Skip to main content
Premium Trial:

Request an Annual Quote

Canada Regulators Approve Meridian's C. Difficile Assay

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience today announced that Health Canada has given an approved medical device license to its molecular amplification assay for Clostridium difficile.

The illumigene C. difficile assay detects the presence of the toxin-producing region from the bacterium and provides highly accurate results in under an hour, the Cincinnati-based company said in a statement. It added that the license announced today positions it in the Canadian market to "provide a full line of C. difficile testing solutions that meet the needs of its clinical lab customers."

The test was recently launched in the US, Australia, Taiwan, and most European markets.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.